Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Brazil for Breast Cancer, NSCLC, CRC, and Malignant Melanoma | Physician & Payer Forum | Brazil and Mexico | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Brazil is highly dependent on incorporation into private and publically funded formularies which vary widely between treatment settings, in terms of drugs and indications covered. As multiple marketed and late-stage emerging agents seek to optimize the market access opportunities offered by targeting premium-priced treatment to those patients most likely to benefit, this report assesses how the rising cost of personalized medicine is balanced with clinical need in breast cancer, non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), and malignant melanoma (MM).
Related Market Assessment Reports
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
